E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Locally Advanced and/or metastatic renal carcinoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050076 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate and compare Progression Free Survival (PFS) of patients treated with pazopanib to those treated with placebo. |
|
E.2.2 | Secondary objectives of the trial |
To compare Overall Survival (OS) of patients treated with pazopanib to those treated with placebo. To evaluate PFS in two subpopulations: the population that has received no prior systemic treatment for locally advanced or metastatic RCC (first-line population), and the population that has received one prior cytokine-based systemic treatment for locally advanced or metastatic RCC (second-line population). To compare Overall Response Rate [ORR = Complete Response (CR) + Partial Response (PR)] in patients treated with pazopanib to those treated with placebo. To compare the rate of CR + PR + 6-months stable disease (SD) in patients treated with pazopanib to those treated with placebo. To assess the incidence, severity and causality of all adverse events (AE), serious adverse events (SAEs) and other safety parameters in patients treated with pazopanib and placebo.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Diagnosis of clear cell RCC that is predominantly clear cell histology.
2. Locally advanced RCC (defined as disease not amenable to curative surgery or radiation therapy) or metastatic RCC (equivalent to stage IV RCC according to AJCC staging.
3. Must have measurable disease, i.e. presenting with at least one measurable lesion per RECIST. A measurable lesion is defined as a lesion that can be accurately measured in at least one dimension with the longest diameter >20 mm using conventional techniques, or >10 mm with spiral CT scan.
4. Must have received a first-line cytokine-based systemic treatment for locally advanced or metastatic RCC with documented disease progression or documented treatment discontinuation due to unacceptable toxicity. Note: The first-line cytokine-based treatment can be interleukin-2 (IL-2) or interferon-alpha (INF-alpha) monotherapy, IL-2 in combination with INF-alpha, IL-2 and/or INF-alpha in combination with chemotherapy or hormonal therapy. Note: Prior adjuvant or neo-adjuvant therapies are permitted excluding any agents that target VEGF or VEGF receptors. The adjuvant/neo-adjuvant therapies should not be considered as first-line systemic treatment for advanced RCC. Exception 1: Patients who live in countries or regions where cytokine therapy is not approved or where there are barriers to the access of such therapies are eligible to participate without receiving a first-line cytokine-based systemic treatment for locally advanced or metastatic RCC. Exception 2: Patients who live in countries or regions where IL-2 or INF- has been approved for the treatment of advanced/metastatic RCC, however, these agents are generally not recognized by the local clinical community as a standard treatment for advanced/metastatic RCC, or where the physician and the patient have determined that the available cytokine therapies are not an acceptable therapeutic option. Exception 3: Patients who have recurred following prior adjuvant or neo-adjuvant cytokine therapy for RCC are eligible to participate without receiving a first-line systemic treatment for locally advanced or metastatic RCC. These patients should be stratified as the first-line population (See section 4 of the protocol).
5. Male or female >=18 years of age
6. ECOG PS 0 or 1
7. Adequate baseline organ function as defined in the protocol |
|
E.4 | Principal exclusion criteria |
1. History of another malignancy. 2. History or presence of central nervous system (CNS) metastasis or leptomeningeal tumors as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam. 3. Presence of uncontrolled infection. 4. History of Class III or IV congestive heart failure according to New York Heart Association (NYHA) classification [See 14.5 Appendix 5 of protocol for description]. 5. Current or prior use of an investigational anti-cancer drug within 4 weeks of start of study. 6. Prior use of an investigational or licensed drug that targets VEGF or VEGF receptors (eg. bevacizumab, sunitinib, sorafinib, etc).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression Free Survival defined as the interval between the date of randomization and the earliest date of disease progression (as defined by the independent reviewer) or death due to any cause. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 54 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last Patient Last Visit, as defined in the protocol |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |